| Catalog No. |
TD-VK617016 |
| Species reactivity |
Human immunodeficiency virus 1 (HIV-1) |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG1, kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
env/Env polyprotein |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P03377 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
KD-247,CAS:914257-21-9 |
| Background |
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |